TO THE EDITOR
In multiple myeloma (MM) patients, treatment with thalidomide has proven its efficacy as monotherapy, but also combined with dexamethasone and chemotherapy. However, in combination with these drugs thalidomide may increase the incidence of deep venous thrombosis and pulmonary embolism up to 30%. 1 The pathogenesis of these thrombotic events is poorly understood and it is also not known how to prevent thalidomide-associated venous thromboembolism (VTE). 2 In patients who were treated in the prospective, multicenter phase III HOVON-50/GMMH-HD3 study, we evaluated the incidence of VTE in newly diagnosed MM patients during induction therapy with thalidomide, doxorubicin and dexamethasone when using the low molecular-weight heparin (LMWH) nadroparine in prophylaxis dosage.
Patients, age 18-65 years, with newly diagnosed MM, Salmon & Durie stage II or III, were eligible for inclusion. Informed consent was obtained from all patients. According to the Declaration of Helsinki, the protocol was approved by the Research Ethics Board of each participating hospital. Patients were randomly assigned to induction chemotherapy consisting of three cycles of vincristine (0.4 mg, i.v. on days 1-4), doxorubicin (9 mg/m 2 , i.v. on days 1-4) and dexamethasone 40 mg orally (days 1-4, 9-12, 17-20), (VAD) arm A. Patients assigned to arm B received thalidomide instead of vincristine (TAD). Cycle 2 starts at day 29, cycle 3 at day 57. Thalidomide was given as 200 mg orally, starting at day 1 of the first TAD cycle and was stopped 2 weeks before chemotherapy for stem cell mobilization was started. The thalidomide dose could be escalated to maximally 400 mg in case of good tolerability. Patients in arm B started with standard dosage thrombosis prophylaxis consisting of subcutaneously LMWH nadroparine 2850 IE anti-Xa or 5700 anti-Xa in case of weight above 90 kg. Prophylaxis was started at day 1 of the first TAD cycle until 1 week before start of chemotherapy for stem cell mobilization. Stem cells were mobilized after cyclophosphamide 1000 mg/m 2 i.v. day 1, doxorubicin 15 mg/m 2 , i.v. on days 1-4, dexamethasone 40 mg orally on days 1-4 (CAD) and G-CSF 5 mg/kg twice daily until collection. After induction therapy all patients received one or two courses of high-dose melphalan (HDM) 200 mg/m 2 with autologous stem cell rescue. Patients randomized to arm A received maintenance therapy with a-interferon (3 Â 10 6 IU, thrice weekly) and patients randomized to arm B received thalidomide 50 mg/day without VTE prophylaxis.
The incidence of VTE was a secondary end point of the study and had to be reported directly by fax to the datacenters as a serious adverse event. The reporting hospitals were then contacted for further details. As control a separate questionnaire was sent to all participating hospitals.
All types of venous thrombosis and pulmonary embolism were included and diagnosis was made by Doppler ultrasonography or spiral pulmonary computer tomography.
The time to occurrence of the first VTE, T VTE , was calculated from the date of randomization. Patients who died within 6 months without VTE were censored at the date of death. T VTE was estimated with the actuarial method of Kaplan and Meier and 95% confidence intervals were calculated, Kaplan-Meier curves of T VTE were generated to illustrate differences between the two treatment arms, and the log-rank test was used to compare the two curves. The reported P-values are two-sided, and a significance level of a ¼ 0.05 was used.
Inclusion In all, 30 cases of VTE were reported in 412 evaluable patients (7%, 95% CI 5-10%) ( Table 1 ). There were 22 lower extremity thrombosis (DVT leg), one DVT leg with pulmonary embolism (PE), four PE and three arm venous thrombosis (DVT arm). One arm venous thrombosis (arm A) was catheter related.
In arm A, 201 patients were included of whom 11 patients developed VTE (5%, 95% CI 3-10%) at a median of 79 days (range 26-164) after randomization. VTE occurred in 19 patients in arm B (9%, 95% CI 6-14%), median 60 days (range 11-182) after randomization (P ¼ 0.15) (Figure 1 ).
Most cases of VTE occurred during induction chemotherapy, eight cases during VAD and 17 cases during TAD (P ¼ 0.08). In arm A, two cases were reported after CAD and one after HDM. In arm B, one patient had a VTE after CAD and one patient after HDM. Two patients in arm B did not receive prophylaxis at the time of VTE while treated with TAD, in one patient prophylaxis was stopped to perform a bone marrow biopsy 1 week before VTE and one patient did not receive prophylaxis for unknown reasons. No side effects, especially bleeding, of nadroparine prophylaxis were reported.
This prospective study shows that with prophylaxis dosage of the LMWH nadroparine the incidence of VTE during combined treatment of thalidomide, dexamethasone and doxorubicin is about 10%. This incidence is comparable with the incidence of VTE during intensive chemotherapy in newly diagnosed MM patients without the use of thalidomide. 3 In the standard VAD arm of this study the incidence of VTE with vigorous monitoring was 5%.
For ethical reasons there was no randomization between patients receiving VTE prophylaxis, because previous publications demonstrated such a high incidence of VTE. Furthermore, in arm B vincristine was left out because of high risk of polyneuropathy when combined with thalidomide. Therefore, only a comparison can be made with historical controls. Zangari et al 1 were the first to report the high incidence of thalidomideassociated VTE of 28% in the Total Therapy II trial during induction therapy with polychemotherapy consisting of vincristine, doxorubicin, dexamethasone, cyclophosphamide, etoposide and cisplatin. Osman et al 4 reported an incidence of 27% in newly diagnosed patients using induction therapy consisting of thalidomide, doxorubicin and dexamethasone in almost similar dosages as in this study. A more recent study combined thalidomide with vincristine, doxorubicin and dexamethasone and reported four thrombotic events in the first 12 patients, that is, an incidence of 33% without the use of VTE prophylaxis, although Zervas et al 5 reported an VTE incidence of 10% with the same regime. (Oakervee H, Brownell A, Cervi P et al. A study of the safety and efficacy of thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) in the treatment of younger patients with multiple myeloma: a UK myeloma forum study. Br J Haematol 2002; 117(Suppl 1): 65, abstract).
These high VTE-incidences are also found in thalidomidebased therapy regimes without anthracyclines and in patients with refractory or relapsed MM patients. 6, 7 Others have tried fixed low-dose warfarin as VTE prophylaxis but reported conflicting results. Zamagni et al used 1.25 mg warfarin daily and demonstrated a decrease in VTE incidence of 26-9% when treating de novo MM patients with dexamethasone and thalidomide. (Zamagni E, Cavo M, Tosi P et al. 
Figure 1
Kaplan-Meier curve of time from randomization to VTE, in months. VAD, vincristine, doxorubicin, dexamethasone. AD þ Thal, thalidomide, doxorubicin, dexamethasone. Survivin is a member of the inhibitors of apoptosis gene family and is abundantly expressed in several cancer entities including hematopoietic malignancies but is undetectable in terminally differentiated adult tissues with only a few exceptions. 1 Survivin could be specifically recognized by the immune system and thus can be regarded as a tumor-associated antigen. 2, 3 Recently, several reports demonstrated that cytotoxic T lymphocytes (CTLs) specific for survivin-derived determinants are capable of efficiently killing leukemia targets endogenously expressing survivin. [3] [4] [5] [6] [7] In the current study, we identified a new HLA-A2-binding epitope, survivin [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] (TLPPAWQPFL) . Using the T2 cellbinding assay, we found that survivin [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] showed comparable binding activity as the positive control peptide FluM1 58-66 (GILGFVFTL, data not shown). CTLs specific for survivin [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] recognized and efficiently killed survivin þ primary malignant cells from patients with chronic lymphatic leukemia (CLL) and acute myeloid leukemia (AML; Figure 1a and c) without attacking HLA-A2-negative tumor cells or normal hematopoietic progenitor cells (Figure 1b and d) . Survivin 5-14 -specific CTLs only recognized and killed T2 cells pulsed with the cognate peptide but spared target cells loaded with a control peptide (survivin 95-104 ; Figure 1e ). Cold target inhibition assays and antibody blocking experiments revealed an MHC class I-restricted killing process induced by peptide-specific CD8 þ T lymphocytes (Figure 1f and g ). Survivin 5-14 -specific CTLs show a high affinity of the peptide/MHC complex, as evidenced by peptide titration assays (Figure 1h) . Furthermore, patient-derived CTLs specific for the survivin [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] peptide are also capable of lysing autologous AML and B-CLL cells (Figure 1i) .
Taken together, the present data and the previous work by the groups of Andersen [3] [4] [5] and Brossart 7 clearly demonstrate that survivin is a useful target molecule for T-cell-based peptide vaccination strategies against both AML and CLL. In a current vaccination study, this issue will be further addressed at our department.
